Search Results

Hello. Welcome to BioFocus, a life science news and insights platform bringing you updates across biotech, pharma, bioprocessing, health, and sustainability. Hello. Welcome to BioFocus. Explore the latest updates from the life science industry. Read more Popular Content. BIOTECH NICE approves first licensed vitiligo treatment for NHS use in England First licensed vitiligo therapy underscores opportunities for innovation, pipeline prioritisation, and market access in autoimmune skin disorders. Featured Articles. HEALTH Sanome Expands NHS Rollout of AI Infection Detection Platform with Innovate UK £300k Read More HEALTH Kaia Health Joins Sword Health to Scale AI-Driven Musculoskeletal Care Read More HEALTH Killing Mosquitoes With the Smell of Flowers Read More BIOPROCESSING FUJIFILM Biotechnologies Launches UK’s Largest Single-Use Biomanufacturing Facility Read More HEALTH Sanome Partners With NHS Trusts to Deploy AI-Powered Clinical Intelligence for Earlier Infection Detection Read More HEALTH A Simple Pad Could Transform Cervical Cancer Screening Read More BIOTECH iXCells and Rosebud Team Up on Human Organoid Models Read More BIOTECH First Human Egg 'Rejuvenation' Offers Hope for Older IVF Patients Read More PHARMA Belite Bio Announces Landmark Phase 3 Success for Stargardt Disease Read More Latest News. 06th March, 2026 01. Sanome Expands NHS Rollout of AI Infection Detection Platform with Innovate UK £300k. Hospital partnerships and £300k Innovate UK SMART funding grant accelerate national deployment of MEMORI for earlier HAI detection Read More 04th March, 2026 02. Mursla Bio joins ABHI US Accelerator for EvoLiver rollout Programme will support US market access and early clinical adoption of the company’s liver cancer surveillance blood test. Read More 23rd February, 2026 03. Broughton expands accredited cannabinoid testing The introduction of ISO/IEC 17025-accredited methods for oils and tinctures reflects rising expectations for analytical robustness as cannabinoid formulations diversify and regulatory scrutiny intensifies. Read More 16th February, 2026 04. NICE approves first licensed vitiligo treatment for NHS use in England First licensed vitiligo therapy underscores opportunities for innovation, pipeline prioritisation, and market access in autoimmune skin disorders. Read More Event Spotlight. Explore the key upcoming industry events. Discover more. Editor's Selects. Weighing the Cost of Semaglutide 01. Read more First Human Egg ‘Rejuvenation’ Offers Hope for Older IVF Patients 02. Read more A Simple Pad Could Transform Cervical Cancer Screening 03. Read more FUJIFILM Biotechnologies Launches UK’s Largest Single-Use Biomanufacturing Facility 04. Read more Stay up-to-date. Connect with BioFocus on LinkedIn or subscribe to our mailing list. Mail

First licensed vitiligo therapy underscores opportunities for innovation, pipeline prioritisation, and market access in autoimmune skin disorders. < Back NICE approves first licensed vitiligo treatment for NHS use in England First licensed vitiligo therapy underscores opportunities for innovation, pipeline prioritisation, and market access in autoimmune skin disorders. The National Institute for Health and Care Excellence (NICE) has approved Opzelura® (ruxolitinib 1.5% cream) for routine NHS use in England, marking the first time a medicine has been specifically licensed and recommended for repigmentation in people with non-segmental vitiligo. Developed by Incyte, the topical Janus kinase (JAK) 1/2 inhibitor is approved for adults and adolescents aged 12 and over with facial involvement (e.g., depigmented patches on the cheeks, forehead, around the eyes or mouth). The decision follows publication of NICE’s Final Draft Guidance and concludes more than two years of negotiation between the company, NHS England and the appraisal body. For the life sciences sector, the recommendation represents a notable regulatory and reimbursement milestone in dermatology, an area where autoimmune-driven skin conditions have historically had limited innovation outside of psoriasis and atopic dermatitis. Autoimmune-driven skin conditions have historically lagged behind other therapeutic areas in terms of licensed, targeted treatments. While diseases like psoriasis and atopic dermatitis now benefit from a range of biologics and JAK inhibitors with robust clinical and real-world data, it is important to note that there is currently no cure for psoriasis, and these treatments primarily manage symptoms and prevent flares rather than eliminating the disease. Many conditions, including vitiligo and alopecia areata, have remained underserved, often relying on off-label therapies or resource-intensive phototherapy. The arrival of a licensed, evidence-based therapy for non-segmental vitiligo demonstrates that dermatology can now offer treatments that are both targeted and clinically validated. It also reflects a broader trend in immune-mediated skin disorders: increasing understanding of disease pathways is enabling the development of precision therapies that address both physical and psychosocial impact. For vitiligo, where the condition’s visibility and psychological burden have historically limited investment, ruxolitinib cream represents both a clinical and regulatory milestone, helping to align dermatology with other autoimmune fields where therapeutic innovation has already transformed patient care. A common but underserved condition Vitiligo is a chronic autoimmune disorder in which melanocytes are progressively destroyed, leading to depigmented patches of skin. It affects around one in 100 people in the UK, with approximately 80% of cases classified as non-segmental vitiligo, the most prevalent form. While not life-threatening, the condition carries a substantial psychosocial burden. Depigmentation is often more visible in people with darker skin tones, and multiple studies have documented elevated rates of anxiety, depression and social withdrawal among those affected. Patient experiences highlight the limitations of the current system. Gill, a 47-year-old pastoral mentor from Preston who has lived with vitiligo for more than three decades, described waiting more than two years for a dermatology appointment before being discharged after ten minutes and told there was “nothing more we can offer you”, a situation patient groups say reflects the limited treatment options historically available. Despite this impact, treatment options within the NHS have largely been limited to off-label topical therapies and phototherapy, with variable outcomes and access constraints. No targeted therapy had previously been licensed in the UK specifically to induce repigmentation. Abbie Hurrell, Chief Executive Officer of The Vitiligo Society, described the approval as “a significant milestone” for an historically overlooked patient population, noting research indicating that 80% of patients feel the condition negatively affects their appearance, and nearly half report isolation or depression. “Vitiligo is a condition that has psychologically devastating effects on people living with it, our own research showed that 80% of patients said vitiligo negatively impacts their appearance and almost half (46%) have suffered with feelings of isolation and depression.” Abbie Hurrell, Chief Executive Officer, The Vitiligo Society Clinical data underpinning approval NICE’s decision is grounded in data from the pivotal Phase 3 TRuE-V1 and TRuE-V2 trials, which enrolled more than 600 patients aged 12 years and older with non-segmental vitiligo. At Week 24, approximately 30% of patients treated with ruxolitinib cream achieved at least a 75% improvement from baseline in the facial Vitiligo Area Scoring Index (F-VASI75), compared with 8–13% in the vehicle arms. By Week 52, around 50% of treated patients reached that threshold. More stringent endpoints (F-VASI90) were achieved by roughly 30% of patients at one year. The safety profile was consistent with previous studies of topical ruxolitinib, with the most common adverse events including application-site acne and pruritus, nasopharyngitis and headache. For clinicians, the availability of a self-administered topical therapy may reduce reliance on resource-intensive phototherapy services, which require repeated hospital visits and can be difficult to access in some regions. Dr Viktoria Eleftheriadou, Consultant Dermatologist, Walsall Healthcare & The Royal Wolverhampton NHS Trusts said: “On behalf of the clinical community, we are delighted that NICE is recommending this treatment option for patients. A topical treatment, Opzelura has the potential to enhance patient and clinical outcomes and serves a huge need in the dermatology community.” Strategic implications for dermatology innovation For Incyte, the NICE endorsement strengthens its inflammation and autoimmunity portfolio in Europe and demonstrates that targeted immunomodulatory therapies can secure reimbursement even in conditions traditionally perceived as cosmetic. Pete Williams, General Manager of Incyte Biosciences UK and Ireland, said the approval followed sustained collaboration with regulators and the patient community to address an area of high unmet need: “This decision is the result of two years of negotiation with NICE and NHSE, and significant collaboration with the patient community to ensure their interests remained at the forefront of decision-makers’ minds.” From a market access perspective, the decision may also signal a broader shift in how health technology assessment bodies evaluate therapies aimed at visible but non-fatal conditions, where quality-of-life gains are central to the value proposition. As with any NICE recommendation, real-world uptake, prescribing patterns and long-term adherence will determine the ultimate clinical and commercial impact. However, for a condition affecting an estimated 600,000 people in the UK, the approval establishes a new treatment benchmark, and may catalyse further R&D investment in pigmentary and autoimmune skin disorders. This approval strengthens the investment case for autoimmune and pigmentary skin disorders, and potentially for other conditions historically dismissed as cosmetic but associated with profound psychological and social burden. It demonstrates that targeted immunomodulatory therapies in dermatology can clear regulatory hurdles and secure payer backing when supported by robust clinical and quality-of-life data, a dynamic likely to influence pipeline prioritisation and capital allocation across the life sciences sector. Author BioFocus Newsroom Previous Next

Biotech Mursla Bio joins ABHI US Accelerator for EvoLiver rollout Programme will support US market access and early clinical adoption of the company’s liver cancer surveillance blood test. Read More NICE approves first licensed vitiligo treatment for NHS use in England First licensed vitiligo therapy underscores opportunities for innovation, pipeline prioritisation, and market access in autoimmune skin disorders. Read More Axol Bioscience acquires Newcells Biotech ophthalmology business Deal strengthens Axol’s position as a leading independent provider of human iPSC-derived retinal models for drug discovery and safety testing. Read More SynGenSys Launches Synthetic Promoter Library for Liver-Targeted Gene Therapies New synthetic promoter tech promises sharper targeting for liver gene therapies Read More iXCells and Rosebud Team Up on Human Organoid Models Partnership integrates scalable iPSC workflows with AI-driven 3D organoids to improve drug safety prediction and translational decision-making in rare diseases. Read More SPT Labtech and Twist Bioscience Team-up to Automate NGS Library Prep Workflows New validated protocols on SPT’s firefly platform aim to boost throughput and reproducibility for sequencing labs. Read More Load more

Health Sanome Expands NHS Rollout of AI Infection Detection Platform with Innovate UK £300k Hospital partnerships and £300k Innovate UK SMART funding grant accelerate national deployment of MEMORI for earlier HAI detection. Read More Prognica Labs and NextGen Immuno Therapeutics Announce Partnership to Advance AI-Driven Precision Immunology Collaboration targets AI-powered immune diagnostics, translational research, and real-world data solutions across high-growth healthcare markets. Read More Kaia Health Joins Sword Health to Scale AI-Driven Musculoskeletal Care The acquisition brings together European digital therapeutics expertise and an AI-first care platform, signalling a new phase for evidence-based MSK care across public and private health systems. Read More A Simple Pad Could Transform Cervical Cancer Screening Population-based study shows menstrual blood testing matches clinic-based HPV detection, with far greater convenience. Read More Killing Mosquitoes With the Smell of Flowers Researchers manipulate killer fungi to lure in and eliminate malaria-carrying mosquitoes. Read More NHS Delivers First CAR-T Treatment for Adult B-cell ALL Patient Pioneering ‘living drug’ offers new hope for adults with aggressive leukaemia. Read More Load more

< Back Prognica Labs and NextGen Immuno Therapeutics Announce Partnership to Advance AI-Driven Precision Immunology Collaboration targets AI-powered immune diagnostics, translational research, and real-world data solutions across high-growth healthcare markets. Prognica Labs and NextGen Immuno Therapeutics have announced a strategic partnership to accelerate the development and deployment of AI-powered immune diagnostics and precision medicine solutions. The collaboration brings together advanced immune profiling and artificial intelligence to support earlier disease detection, improved patient stratification, and more informed clinical decision-making. Headquartered in Dubai and Vienna respectively, the two companies will focus on expanding precision immunology capabilities across high-growth healthcare markets, including the Gulf Cooperation Council, India, and the United States. The partnership reflects increasing global demand for diagnostic platforms capable of translating complex biological data into clinically actionable insights. Combining immune profiling and AI analytics The partnership integrates NextGen Immuno Therapeutics’ immune profiling platform with Prognica Labs’ AI-driven analytics infrastructure. NextGen’s technology analyses immune system signals from blood samples to generate patient-specific insight reports, enabling clinicians to assess disease risk, guide treatment selection, and monitor therapeutic response. Prognica Labs will enhance these capabilities by applying AI-based predictive modelling, real-world evidence generation, and health data integration. Together, the companies aim to provide healthcare providers and pharmaceutical partners with more precise diagnostic tools while strengthening the evidence base required for regulatory and clinical adoption. Khalid Shaikh, Founder & CEO of Prognica Labs, said: “The future of drug discovery lies in precision, not probability. This partnership bridges translational immunology with AI-powered decision systems. In markets like GCC, India, and the United States, where oncology burden is rising sharply, we are building not just a diagnostic solution - but an ecosystem for early detection, patient stratification, and cost-efficient care delivery.” Expanding precision immunology across healthcare systems The collaboration will support the deployment of immune diagnostics across hospital networks, transplant centres, cancer institutes, and public health programmes. By combining AI with immune profiling, the partnership seeks to enable earlier clinical intervention and reduce uncertainty in treatment selection, particularly in oncology and immune-mediated diseases. Dr. Ram Vinay Pandey, Founder & CEO of NextGen Immuno Therapeutics, said: “Immune profiling is the missing layer in personalized medicine. Our platform translates complex immunological signals into clinically actionable insights. By partnering with Prognica Labs, we are accelerating our mission to move from isolated clinical pilots to scalable global deployment - bringing immune foresight to medicine before it’s too late.” The ability to convert immune system data into predictive insights has implications not only for individual patient care, but also for clinical trial design and therapeutic development. Immune biomarkers can help identify which patients are most likely to respond to treatment, improving clinical outcomes while reducing development timelines and costs. Supporting drug development, clinical research, and public health The partnership also aims to strengthen translational research by integrating immune data with AI-driven analytics. This approach enables pharmaceutical companies and healthcare providers to better understand disease progression, optimise treatment pathways, and generate real-world evidence to support regulatory and commercial strategies. Dr. Sujay Patil, Chief Scientific Officer at Prognica Labs, said: “From a scientific standpoint, integrating immune profiling with advanced AI analytics represents a paradigm shift in how we approach oncology and immune-mediated diseases. Immune signatures provide early biological signals long before clinical deterioration becomes evident. By combining high-dimensional immunological data with predictive modeling, we can improve patient stratification, reduce therapeutic trial-and-error, and generate real-world evidence that strengthens both clinical decision-making and regulatory confidence.” Positioning precision immunology for global scale Healthcare systems worldwide are increasingly investing in data-driven infrastructure and precision medicine approaches. The integration of AI with immune diagnostics offers a pathway to more proactive and personalised care, particularly in oncology, transplant medicine, and autoimmune disease management. By combining advanced immunology platforms with scalable AI infrastructure, Prognica Labs and NextGen Immuno Therapeutics are positioning their partnership at the intersection of diagnostics, therapeutics, and digital health. As healthcare providers and pharmaceutical companies seek more precise tools to guide treatment and accelerate development, integrated immune intelligence platforms are expected to play an increasingly central role in the future of medicine. Author BioFocus Newsroom Previous Next

< Back Sanome Expands NHS Rollout of AI Infection Detection Platform with Innovate UK £300k Hospital partnerships and £300k Innovate UK SMART funding grant accelerate national deployment of MEMORI for earlier HAI detection. Sanome is accelerating the NHS deployment of its AI-powered infection detection platform following two new hospital partnerships and the award of an Innovate UK SMART grant worth over £300,000. Part of the national innovation funding programme, SMART grants provide financial support for feasibility studies, industrial research or experimental development projects, typically backing early- to mid-stage R&D that has strong market potential and clear economic or societal benefit. The UK healthtech company’s platform, MEMORI, became the country’s first multimodal Class IIb CE-marked AI Software as a Medical Device for infection prediction last year. Designed to detect hospital-acquired infections (HAIs) sooner than standard practice, MEMORI analyses real-time patient data and integrates directly into electronic patient record (EPR) systems, bringing predictive insight into clinicians’ existing workflows. The current state of the NHS Although there is now very definitely light at the end of the tunnel, the winter of 2025 to 2026 has again tested NHS capacity. Delayed discharges have placed sustained strain on hospital flow, with the proportion of bed days occupied by patients medically fit for discharge rising from 10.1% in 2024 to 11% in 2025. That 9% increase equates to approximately 19,000 additional bed days, further limiting available capacity during peak seasonal demand. Reduced bed availability has a direct knock-on effect across urgent and emergency care, contributing to congestion in emergency departments and longer waits during periods of heightened activity. Yet the picture is not solely one of pressure. Despite battling what has been described as the busiest winter on record, NHS England recently reported that the elective care waiting list has fallen to its lowest level in nearly three years. The data signals steady progress in recovery efforts even as operational challenges persist. This dual reality, persistent system strain alongside measurable improvement, underscores the importance of tools that can prevent avoidable deterioration. Earlier identification of infection risk has the potential to shorten hospital stays, reduce complications, and ease pressure on constrained bed capacity. Furthermore, HAIs remain one of the most serious and costly challenges facing the NHS, contributing to over seven million additional patient bed days and £2.7 billion in annual care costs. Early detection is critical for preventing deterioration, easing clinical pressures, and improving patient outcomes. Two hospital partnerships extend national footprint Against this backdrop, Sanome has confirmed new partnerships with the Royal Hospital for Neuro-disability and East Kent Hospitals University NHS Foundation Trust. Back in December 2025, the Royal Hospital for Neuro-disability became the first specialist neuro facility to embed MEMORI into routine care, first integrating with the PatientSource EPR to cover four wards. Patients with complex neurological conditions are among the most vulnerable to infection-related complications; more than six in ten intensive care patients contract at least one hospital-acquired infection during their stay. East Kent Hospitals University NHS Foundation Trust, one of England’s largest acute trusts, will also deploy MEMORI within its EPR infrastructure. The collaboration is intended to establish a scalable model for secure, real-time NHS data access across multiple hospital sites. Hospital-acquired infections (such as pneumonia, methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. difficile)) remain a major clinical and financial burden, accounting for more than 7.1 million excess bed days and an estimated £2.7 billion in annual costs. Research indicates that between 35% and 55% of infections may be preventable with earlier detection and intervention. MEMORI uses explainable clinical AI to identify emerging infection risk from multimodal data streams. Early studies associated with the certified product have shown the potential to surface life-threatening infection predictions up to three days earlier than standard practice. Preliminary data also indicate it outperforms the NHS-standard National Early Warning Score (NEWS2) system in detecting deterioration. “Partnering with leading healthcare organisations like the Royal Hospital for Neuro-disability and East Kent Hospitals University NHS Foundation Trust marks another major step towards bringing earlier, data-driven infection detection into everyday care for every patient,” said Benedikt von Thüngen, Founder and CEO of Sanome. “Working closely with clinicians, we’ve co-created a platform that not only flags those at risk but fits seamlessly into existing workflows. Our aim is to equip frontline teams with the actionable insights they need to intervene sooner and protect patients, at the same time relieving pressure on already-stretched resources.” Beyond rollout at the Royal Hospital for Neuro-disability and East Kent Hospitals University NHS Foundation Trust, additional NHS deployments are planned throughout 2026 with initial data suggesting MEMORI outperforms the NHS-standard National Early Warning Score (NEWS2) system in detecting deterioration. Innovate UK funding supports next-generation development Alongside the hospital rollouts, Sanome has secured an Innovate UK SMART grant in collaboration with the NIHR HealthTech Research Centre in Sustainable Innovation to advance MEMORI’s next phase of development (termed MEMORI v2). The 18-month programme will support enhancements to the platform, including integration of additional multimodal data inputs such as laboratory results, prescriptions and clinical notes. It will also focus on further scalable EPR integration, improved explainability, and optimisation of machine-learning performance. The project aims to increase predictability by a further 20%, extending the window for early intervention and ultimately increasing the chance of saving lives. MEMORI alerts clinical teams up to seven days before signs of infection, creating additional time to act before symptoms escalate. MEMORI v2 will undergo large-scale live validation across multiple wards at Royal Devon University Healthcare NHS Foundation Trust, targeting one of the NHS’s most persistent patient safety challenges. “Our mission is to prevent deterioration before it becomes life-threatening. MEMORI shows how real-world NHS data, when safely and securely unlocked, can be transformed into actionable bedside insights that change outcomes using the power of multimodal AI. Working with the Exeter HealthTech Research Centre, with support from Innovate UK, allows us to demonstrate both the clinical and system-wide benefits of AI in one of the UK’s leading NHS Trusts,” said von Thüngen. Dr Nick Kennedy, Digital Innovation and AI Theme Lead at the NIHR HRC in Sustainable Innovation and Consultant Gastroenterologist at the Royal Devon, added: “Hospital-acquired infections remain one of the biggest threats to patient safety, particularly for vulnerable patients with complex conditions. That means early intervention is vital. By co-designing MEMORI with the support of Innovate UK, we are proud to be among the first to test such technology and show how AI can support clinicians, transform patient care and ultimately save lives.” Chris Sawyer, Innovation Lead Digital Health, Innovate UK added: “Supporting the safe introduction of AI into frontline NHS care is a vital step towards building a more resilient and patient-centred health service. This partnership with Sanome and Royal Devon is a strong example of how innovation and clinical expertise can come together to tackle long-standing challenges like hospital-acquired infections.” The first impact data from the large-scale deployment is expected later in 2026, alongside further rollout across NHS and healthcare organisations in the UK. As NHS leaders continue to balance recovery targets with sustained operational pressure, technologies that promise to prevent avoidable deterioration are likely to attract growing interest. Now embedded in routine care at the Royal Hospital for Neuro-disability, and going live in NHS settings including East Kent Hospitals University NHS Foundation Trust and Royal Devon University Healthcare NHS Foundation Trust in the coming months, each new deployment will contribute to a growing body of real-world outcome data. Building on encouraging early findings, this next phase will generate the robust evidence needed to further validate clinical impact, refine integration across diverse NHS environments, and demonstrate system-wide cost-effectiveness. Frontline staff experience will remain central to that process, ensuring MEMORI continues to support clinical judgement, reduce cognitive burden, and enhance rather than disrupt the workflows of the teams it is designed to serve. Author BioFocus Newsroom Previous Next

Programme will support US market access and early clinical adoption of the company’s liver cancer surveillance blood test. < Back Mursla Bio joins ABHI US Accelerator for EvoLiver rollout Programme will support US market access and early clinical adoption of the company’s liver cancer surveillance blood test. UK–US biotech company Mursla Bio has been selected to join the Association of British HealthTech Industries (ABHI) ABHI US Accelerator, a programme designed to help health technology companies establish and expand their presence in the US healthcare market. The company plans to use the initiative to support the commercial deployment of EvoLiver, its FDA-designated blood test for liver cancer surveillance, across US health systems, payors and clinical stakeholders. Participation in the accelerator will provide structured access to more than 300 senior healthcare leaders across 35 hospitals, 20 health systems and US insurers. The programme also offers operational guidance from organisations including Becton Dickinson and Dell Medical School at the University of Texas, as well as ABHI’s US advisor network. Mursla Bio said the connections are expected to support EvoLiver’s integration into clinical workflows and help translate launch readiness into early adoption among specialist hepatology centres. Preparing for US launch The company is continuing preparations for the US introduction of EvoLiver, including CLIA laboratory readiness, engagement with key opinion leaders and clinical societies, and dialogue with payors. EvoLiver is designed as a blood-based surveillance test for high-risk patients, using hepatocyte-specific extracellular vesicle biology to improve the detection of liver cancer and address limitations associated with standard monitoring approaches. Liver cancer remains one of the fastest-growing causes of cancer-related mortality in the United States. According to Mursla Bio, challenges in surveillance performance and patient adherence contribute to late diagnosis, creating an opportunity for improved diagnostic tools. The company said its initial commercial strategy will focus on hepatology-led adoption aligned with clinical guidelines, with broader expansion planned as further clinical evidence supports wider coverage and use. Building US healthcare connections Commenting on the announcement, Pierre Arsène, Founder and CEO of Mursla Bio, said: “Bringing a new test into clinical use depends on reaching the right people across the healthcare system. This programme strengthens those connections while supporting EvoLiver’s early deployment and laying the commercial foundations for our EV diagnostics platform in the US.” Platform approach to diagnostics Mursla Bio’s work centres on extracellular vesicle (EV) science and what it describes as a “Dynamic Biopsy” approach. The technology is designed to non-invasively analyse biological processes within a specific organ or tissue by isolating organ-specific EVs from biofluids. These vesicles are analysed through a multi-omics workflow spanning proteins, miRNAs and mRNAs, supported by an AI-enabled platform for biomarker discovery and assay development. EvoLiver represents the first clinical application of this approach, with the company initially focused on improving liver cancer surveillance in high-risk populations before expanding into additional precision medicine applications. Headquartered in Cambridge, UK, with operations in Boston, Massachusetts, Mursla Bio is positioning the US as a key early market for its extracellular vesicle-based diagnostics platform. Author BioFocus Newsroom Previous Next

< Back 7th – 9th August, 2024 Philadelphia, PA Immuno-Oncology Summit 2024 CHI’s Immuno-Oncology Summit has grown to be the premier annual meeting for advancing biotherapeutics. This summit offers a comprehensive 3-day 6-track program, exploring bi- and multispecific biotherapeutics; highlighting the latest developments in CAR T therapies, emerging targeting technologies, personalized immunotherapy, and cell-based immunotherapies; and addressing the challenges of overcoming tumor resistance. Previous Book your place Next

< Back 16th – 19th June, 2025 Boston, MA 2025 BIO International Convention The BIO International Convention is the world’s largest biotechnology event, bringing together industry leaders from around the world to learn, network, and build relationships. The convention is produced by the Biotechnology Innovation Organization (BIO), the world’s largest advocacy association for biotechnology. Previous Book your place Next

< Back 30th June – 3rd July, 2024 Rotterdam, Netherlands ECB2024 The Dutch Biotechnology Association (NBV) is pleased to host the World’s two longest running biotechnology Congresses, ECB2024 and IBS2024, at their annual meeting, NBC-24, in the Netherlands. Previous Book your place Next

< Back 17th March, 2026 Philadelphia, PA Rare Disease Summit Accelerating innovation and commercial success in rare disease care. The Rare Disease Summit, taking place March 17–19, 2026 in Philadelphia, PA, brings together cross-functional leaders from biotech, pharma, payers, patient advocacy groups, and service partners to drive therapeutic innovation where medical need is greatest. This three-day event delivers actionable insights on launch planning, market access, reimbursement strategies, and strategic partnerships that shape successful rare disease commercialization. Through expert-led sessions, real-world case studies, and collaborative discussions, attendees will explore emerging trends, optimize value demonstration, and strengthen approaches to elevate patient impact across rare disease communities. Previous Book your place Next

< Back 24th - 26th February, 2026 London, UK 9th Annual CAR-TCR Summit Europe Connect with Europe's leading companies and research centres to stay ahead in innovation, strengthen manufacturing capabilities, and build the partnerships needed to drive the next generation of life-saving cell therapies across the continent and beyond. Cell therapy is at a pivotal moment, with global investment and innovation reshaping the landscape. While funding challenges persist, Europe and Asia are emerging as hotspots for rapid clinical development and strategic partnerships. The rise of in-vivo CAR-T and next-generation TCR approaches highlights a shift toward scalable, cost-effective therapies that could transform patient access and commercial feasibility. Returning to London for its 9th year, the CAR-TCR Summit Europe is the essential forum to gain cutting-edge scientific insights, practical manufacturing strategies, and business intelligence to accelerate clinical success. Attendees will explore advances in novel CAR and TCR designs, armouring, and engineered signalling pathways, while also learning how leading institutions are improving scale, automation, and point-of-care solutions to reduce costs and enhance reliability. Previous Book your place Next